Search

Introduction: In the present study, citrus pectin-stabilized copper/iron bimetallic nanoparticle (NP) catalyst has been used for the degradation of methylene blue (MB) dye in wastewater produced from the food industry. Methods: The P@Cu/Fe composites were synthesized by co-precipitation and the sol-gel methods. Results and discussion: The characterization of the composites was carried out using UV, FTIR, SEM, and XRD techniques, revealing that P1@Cu/FeNPs synthesized through co-precipitation had a particle size of 150-35 nm with an irregular spherical and hexagonal shape. P2@Cu/FeNPs, synthesized using the gel combustion method using triethylamine as fuel, proved to be a better nanocatalyst with spherical particles having a uniform structure and size distribution of 105-23 nm. The mean zeta potential value of P1@Cu/FeNPs was found to be between 0 and 5mv, showing the composite to be less stable and 13 mv for more stable P2@Cu/FeNPs. The degradation of MB by P1@Cu/FeNPs was recorded up to 23.57% after 35 min and the nanocomposite synthesized by the sol-gel method exhibited 97.28% degradation in 30 min. The P2@Cu/FeNPs performed the best degradation due to their synergistic impact. In essence, this research represents a step toward the synthesis of bimetallic NPs using a biomaterial (citrus pectin) with improved synergistic photocatalytic potential that can induce different features in nanomaterials. Pectin-functionalized NPs using different metals should be synthesized and tested for different catalytic applications. [ABSTRACT FROM AUTHOR]

Considering patient underwent endoscopy recently; CT findings were attributed to aspiration pneumonia and patient was discharged on augmentin. B Introduction: b Pulmonary nocardiosis is a rare disease caused by inhalation of bacteria from genus Nocardia from soil. [Extracted from the article]

Despite current standard of care treatment, the period shortly after acute myocardial infarction (AMI) is associated with high residual cardiovascular (CV) risk, with high rates of recurrent AMI and CV death in the first 90 days following the index event. This represents an area of high unmet need that may be potentially addressed by novel therapeutic agents that optimize high-density lipoprotein cholesterol (HDL-C) function rather than increase HDL-C concentrations. Apolipoprotein A-I (apoA-I) is the major constituent of HDL and a key mediator of cholesterol efflux from macrophages within atherosclerotic plaque, a property especially relevant during the high-risk period immediately following an AMI when cholesterol efflux capacity is found to be reduced. CSL112 is a novel formulation of human plasma-derived apolipoprotein A-I (apoA-I), currently being evaluated in a Phase 3 clinical trial (AEGIS-II) for the reduction of major adverse CV events in the 90-day high-risk period post-AMI. In this review, we provide an overview of the biological properties of CSL112 that contribute to its proposed mechanism of action for potential therapeutic benefit. These properties include rapid and robust promotion of cholesterol efflux from cells abundant in atherosclerotic plaque, in addition to anti-inflammatory effects, which together, may have a stabilizing effect on atherosclerotic plaque. We provide a detailed overview of these mechanisms, in addition to information on the composition of CSL112 and how it is manufactured., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)